Two GLP-1/glucagon dual agonists, developed an ocean apart by Boehringer Ingelheim and Innovent Biologics, are testing whether adding back a hormone that normally raises blood sugar can still produce a net metabolic win.
Survodutide
-
Survodutide and Mazdutide: The Glucagon Bet